Experience with Cyproterone Acetate in the Treatment of Precocious Puberty

@article{Laron2000ExperienceWC,
  title={Experience with Cyproterone Acetate in the Treatment of Precocious Puberty},
  author={Zvi Laron and Rivka Kauli},
  journal={Journal of Pediatric Endocrinology and Metabolism},
  year={2000},
  volume={13},
  pages={805 - 810}
}
  • Z. Laron, R. Kauli
  • Published 2000
  • Medicine
  • Journal of Pediatric Endocrinology and Metabolism
The authors review their experience (1967-present) in the use of cyproterone acetate (CPA) in precocious puberty. CPA was found effective in persistently suppressing pituitary gonadotropic secretion when administered orally at a dose of 50 mg b.i.d. (70-100 mg/d). After the introduction of gonadotropic analogues (GnRHa) for treatment of central precocious puberty, short term use of CPA was found useful to counteract the initial stimulatory effect of the GnRHa as well as an adjunct drug in case… Expand
Central Precocious Puberty in an Infant with Sotos Syndrome and Response to Treatment.
TLDR
A case of Sotos syndrome diagnosed at the infancy period with central precocious puberty is reported, and leuprolide acetate in maximum dose could not be successful for the control of pubertal progression, and cyproterone acetate was added to therapy. Expand
A Practical Approach to Precocious Puberty
TLDR
At this followup visit, her growth velocity was determined to be 7 cm per year with a BA of 10 years, and the FSH and LH response to GnRH stimulation is suppressed and growth rate has decreased appropriately. Expand
Adult height following a combined treatment of ketoconazole — cyproterone acetate — leuprolide depot in a boy with atypical McCune-Albright syndrome
TLDR
In a MAS boy presenting with unilateral macroorchidism and no other signs of PPP, a consecutive involvement of Leydig cells may follow the initially isolated activation of Sertoli cells, as demonstrated by the very good adult height outcome recorded in this patient. Expand
Central Precocious Puberty
TLDR
Treatment preserves height potential in the majority of patients and improves the final adult height of children with rapidly progressing CPP, with a complete recovery of the hypothalamic-pituitary-gonadal axis after treatment. Expand
Anti-androgens for the treatment of hirsutism
  • E. Carmina
  • Medicine
  • Expert opinion on investigational drugs
  • 2002
TLDR
The most common anti- androgen agents are discussed in this review and the importance of diagnosis in choosing the most appropriate anti-androgen treatment is also discussed. Expand
Disorders of Puberty: Pharmacotherapeutic Strategies for Management.
  • M. Zacharin
  • Medicine
  • Handbook of experimental pharmacology
  • 2019
TLDR
This paper describes pharmacologic interventions used for pubertal disorders but is not intended to address the diagnostic cascade in detail. Expand
Effect of GnRH analogue on predicted adult height in girls with early puberty
TLDR
The growth promoting effect of GnRHa in girls with early puberty and low predicted adult height and the hope that interrupting puberty might increase adult height is analyzed. Expand
Long‐term treatment of familial male‐limited precocious puberty (testotoxicosis) with cyproterone acetate or ketoconazole
Background  Familial male‐limited precocious puberty (FMPP) or testotoxicosis is a rare gonadotrophin‐independent form of sexual precocity caused by constitutively activating mutations of the LHExpand
OVERCOMING TREATMENT RESISTANCE OF DEPRESSION IN AN ADVANCED AGE FEMALE PATIENT WITH ADDISON DISEASE: A LITERATURE REVIEW WITH CLINICAL CASE PRESENTATION
Purpose. To provide the reader with a systematic review of the literature regarding the relationship of major depressive disorder (and mental disorders in general) with adrenal cortex insufficiency,Expand
A Case of X-Linked Adrenal Hypoplasia Congenita, Central Precocious Puberty and Absence of the DAX-1 Gene: Implications for Pubertal Regulation
TLDR
The fact that a ‘loss of function’ DAX-1 mutation can be associated with hypog onadotropic hypogonadism, precocious and normal puberty, suggests that DAx-1 is but one of several transcription factors which regulate puberty, and provides further evidence that other transcription factors may interact with DAX -1 and influence gonadal regulation in a complex, but hierarchical fashion. Expand
...
1
2
...

References

SHOWING 1-10 OF 38 REFERENCES
Treatment of Precocious Puberty with Cyproterone Acetate
TLDR
It is concluded that cyproterone acetate in the dosage used is without effect on growth and would therefore be expected not to prevent short adult stature in patients with precocious puberty and with other respects it is effective through its antiandrogenic and gonadotropin-inhibiting properties. Expand
Cyproterone acetate in treatment of precocious puberty.
TLDR
It is concluded that at present cyproterone acetate by mouth is the drug of choice in the treatment of precocious puberty and the treatment should be initiated as early as possible to attain maximum benefit. Expand
Cirrhosis in a child with hypothalamic syndrome and central precocious puberty treated with cyproterone acetate
TLDR
Prolonged cyproterone acetate treatment may induce cirrhosis in a 10-year-old boy with hypothalamic syndrome and precocious puberty who was treated with CPA for over 50 months and died of sepsis and multiorgan failure at the age of 14 years. Expand
ADRENOCORTICAL FUNCTION IN CHILDREN WITH PRECOCIOUS SEXUAL DEVELOPMENT DURING TREATMENT WITH CYPROTERONE ACETATE
TLDR
It was concluded that despite the evidence of adrenal suppression by CPA, cortisol supplementation is not necessary and may even be contra‐indicated. Expand
Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method.
TLDR
It is concluded that without treatment the FHt of girls with CPP may be significantly compromised and that therapy is more beneficial if started before bone age exceeds 12 years, regardless of the advanced bone age of the patients. Expand
Effect of cyproterone acetate therapy on gonadotropin response to synthetic luteinizing hormone-releasing hormone (LRH) in girls with idiopathic precocious puberty.
TLDR
Plasma gonadotropin pattern following exogenously administered luteinizing hormone-releasing hormone (LRH), orally administered for 8 to 35 months to 7 girls with idiopathic precocious puberty, was characterized before treatment by an exaggerated LH response; plasma FSH response was similar to prepubertal subjects. Expand
Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism.
TLDR
Following termination of the medication, the various symptoms of virilism reappeared more or less quickly and markedly in the majority of the patients unless they are placed on oral contraceptives containing a derivative of 17-acetoxyprogesterone. Expand
The LH response to LH releasing hormone in children with true isosexual precocious puberty treated with cyproterone acetate.
TLDR
It was found that cyproterone acetate induces suppression of the responsiveness of the pituitary gland to secrete LH on LHRH stimulation and daily oral therapy was found to be more effective than the regimen of intramuscular depot injections. Expand
Constitutional Isosexual Precocious Puberty: Effects of Medroxyprogesterone Acetate Therapy
TLDR
The selection of ages demarcating "normal" from "precocious" may be based on the observations of Nicolson and Hanley, who found the earliest pubertal changes in North American girls to occur at a mean age of 10.6 years with a standard deviation of 1.2 years. Expand
D-TRP6-ANALOGUE OF LUTEINISING HORMONE RELEASING HORMONE IN COMBINATION WITH CYPROTERONE ACETATE TO TREAT PRECOCIOUS PUBERTY
A 6-year-old girl with central (true) precocious puberty was successfully treated with a combination of the luteinising hormone releasing hormone analogue (D-Trp6)-LH-RH and cyproterone acetate. ThisExpand
...
1
2
3
4
...